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NOVEL POLG VARIANTS ASSOCIATED WITH
LATE-ONSET DE NOVO STATUS EPILEPTICUS
AND PROGRESSIVE ATAXIA
Mitochondrial disease is phenotypically and geneti-
cally heterogeneous with an estimated prevalence of
1 in 4,300.1 Mutations in the POLG gene, encoding
the catalytic subunit of DNA polymerase gamma, are
an important cause of mitochondrial disease. The
spectrum of clinical manifestations in POLG-related
mitochondrial disease is variable,2 with disease onset
ranging from adulthood-onset dominant or recessive
progressive external ophthalmoplegia (chronic progres-
sive external ophthalmoplegia), ataxia-neuropathy
spectrum, myoclonic epilepsy, myopathy, and sensory
ataxia to childhood-onset Alpers syndrome, which is
characterized by intractable seizures, psychomotor
regression, and hepatic impairment. Epilepsy is a poor
prognostic factor in POLG mutations,3 and the onset
of epilepsy often clusters in childhood (,5 years) and
teenage.4 However, late-onset epileptic encephalopathy
is uncommon.4,5 Herein, we describe a patient who
died of de novo, late-onset refractory status epilepticus
with the identification of 2 novel variants in the POLG
gene.
Case report. A 69-year-old woman presented with
an 8-year history of slowly progressive gait ataxia
associated with dysarthria to the regional ataxia cen-
ter. She also noted to have generalized myoclonic
jerks for 9 months. There was no other medical his-
tory or relevant family history of any neurologic dis-
order. On examination, she had evidence of
ophthalmoplegia in all directions of gaze. She was
found to have prominent gait and lower limb ataxia.
Myoclonus was demonstrable with outstretched
arms. Reflexes were present and symmetrical. She was
just able to walk with a stick and required 1 person’s
assistance. Mitochondrial disease was suspected, and
she underwent a muscle biopsy.
She was admitted acutely to the hospital following
2 episodes of generalized tonic-clonic seizures at age
71. She was treated with IV phenytoin and levetirace-
tam. Her management was rapidly escalated to the
administration of general anesthesia due to convulsive
status epilepticus. Laboratory investigations including
routine biochemistry, autoantibodies, septic screens,
and CSF analysis were unremarkable, except
a slightly raised serum lactate level at 3.3 mol/L
(normal: ,2.2 mmol/L). EEG showed encephalo-
pathic changes. MRI head T2 and fluid attenuation
and inversion recovery sequences revealed stroke-
like lesions (figure, A), in addition to the previously
documented changes in the clinic (figure, B). Epi-
lepsia partialis continua, affecting the left face, arm,
and leg, emerged on day 12 of admission. Her seiz-
ures were suprarefractory to treatment, despite
receiving a combination of phenytoin, levetirace-
tam, clonazepam, propofol, midazolam, and pulse
methylprednisolone. She died of worsening epilep-
tic encephalopathy and multiorgan failure after 2
weeks of hospitalization.
This patient was tested negative for common mito-
chondrial DNA (mtDNA) point mutations, including
m.3243A.G, m.8344A.G, and m.8993T.C/G.
She was also tested negative for 3 common POLG
mutations (p.Ala467Thr, p.Trp748Ser, and p.
Gly848Ser). Her muscle biopsy revealed histochemical
and molecular genetic evidence of mitochondrial dys-
function, including cytochrome c oxidase–deficient
fibers (figure, C) and variable mtDNA deletions (fig-
ure, D). No pathogenic variant was identified in
TWNK and RRM2B. Direct sequencing of the POLG
gene (GenBank accession number NM_002693.2)
identified 2 rare variants, c.1232T.C, p.(Leu411Pro)
and c.1721G.A, p.(Arg574Gln), both affecting
conserved amino acids and predicted to be damaging
(figure, E). Familial segregation studies were not fea-
sible, as she was the only child and both her parents
were deceased.
Discussion. Our patient’s initial presentation of
a progressive cerebellar ataxia plus other neurologic
features including external ophthalmoplegia and
myoclonus is highly suggestive of a mitochondrial
etiology. Moreover, her neuroimaging findings of
bilateral signal abnormalities in thalami, cerebellar
dentate nuclei, and cerebellar atrophy have previously
been reported in POLG-related mitochondrial dis-
ease.6 However, the development of fatal epileptic
encephalopathy is rather surprising, given the insidi-
ous onset of her illness. Our case highlights the pro-
gressive nature of POLG-related mitochondrial
disease, the overlap of clinical syndromes and
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difficulty of predicting the trajectory of disease pro-
gression, and the management challenge of refractory
mitochondrial epilepsy.4 The presence of focal onset
motor status, together with the acute stroke-like le-
sions, is likely related to the neuronal energy failure6
of which inhibitory interneurons have been shown
to be particularly vulnerable to mitochondrial
dysfunction.7
We were unable to unequivocally conclude
whether these 2 variants were in cis or in trans. We
speculate that our patient had a late-onset recessive
POLG disease, given that recessive POLG disease is
more common than dominant presentations accord-
ing to our experience and reported cases in the liter-
ature. Both variants are located in the linker domain
of POLG, and we have recently showed that muta-
tions (homozygous or compound heterozygous) in
this region are associated with later disease presenta-
tion and longer survival compared with other do-
mains within the POLG protein.4
Figure Neuroimaging, muscle biopsy, and molecular genetic findings
(A) Head MRI performed at age 71 following admission in status epilepticus. Diffusion-weighted imaging sequence showed
restricted diffusion in occipital, parietal, and frontal lobes, thalami, and with low ADC map in the right frontal lobe (red
arrow). (B) Head MRI performed at onset of ataxia aged 69. Sagittal T1 view showed cerebellar atrophy and axial T2 view
showed symmetrical hyperintensities in the cerebellar dentate nuclei and thalami. (C) Sequential cytochrome c oxidase
(COX)–succinate dehydrogenase histochemistry demonstrates a mosaic distribution of COX-deficient muscle fibers (blue)
among fibers exhibiting normal COX activity (brown). (D) Long range PCR amplification of muscle DNA across the major arc
confirms multiple mitochondrial DNA (mtDNA) deletions in patient muscle (lane 1) compared with age-matched control
muscle (lane 2); MW 5 molecular weight marker. (E) Alignments of mutation-containing POLG regions across multiple
species show the evolutionary conservation of the heterozygous c.1232T.C, p.(Leu411Pro) and c.1721G.A, p.
(Arg574Gln) missense POLG variants. The c.1232T.C, p.(Leu411Pro) variant is absent from both the ExAC browser (exac.
broadinstitute.org)and the NHLBI ESP (evs.gs.washington.edu/EVS/) database (both accessed on October 6, 2016), thus
representing a novel missense change, while the c.1721G.A, p.(Arg574Gln) variant has only identified in 3/120480 alleles
on the ExAc browser. A different POLG variant affecting the same amino acid c.1720C.T, p.(Arg574Trp) has been pre-
viously reported in trans with other known pathogenic variants in 4 unrelated patients, according to the Human DNA
Polymerase Gamma Mutation Database (tools.niehs.nih.gov/polg/index.cfm/main/search) (accessed on May 17, 2017).
Affected amino acids are highlighted by an asterisk; sequence identity is shown by bold, red typeface.
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We propose that POLG-related mitochondrial dis-
ease should be a differential diagnosis in cases of de novo
status epilepticus, particularly with other clinical features
such as ataxia and external ophthalmoplegia, irrespective
of age. Full sequencing of POLG should be performed
because more than 20% of patients do not carry 1 of the
3 common mutations,4 as exemplified by this case.
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